Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Wei Yee ChanNicholas CounsellRuth de TuteDunnya De-SilvaElizabeth H PhillipsJamie CavenaghToyin AdedayoNivette BragancaClaire RoddieMatthew StreetlyStephen ScheyMickey B C KohJosephine CroweTreen C MorrisCurly T C M MorrisLaura Clifton-HadleyNeil RabinRoger G OwenRakesh PopatKwee L Yongnull nullPublished in: British journal of haematology (2021)
Keyphrases
- phase ii
- newly diagnosed
- multiple myeloma
- stem cells
- clinical trial
- open label
- phase iii
- cell therapy
- placebo controlled
- double blind
- bone marrow
- locally advanced
- low dose
- high dose
- free survival
- platelet rich plasma
- study protocol
- randomized controlled trial
- radiation therapy
- squamous cell carcinoma
- adipose tissue
- mesenchymal stem cells
- weight loss